

### **Carotid Artery Disease**

How the 2014-2015 Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient

Christopher J. White, MD, MSCAI, FACC, FAHA, FESC
Professor and Chair of Medicine
Ochsner Clinical School and Ochsner Medical Center
New Orleans, LA



## DISCLOSURE

#### Relevant to Carotid Artery Stenting

• Relationships with industry:

- Research: None

Stock Ownership: None

Speakers Bureau: None

- Consultant: None



"So, I'm the only one who sees a conflict of interest here?"



### Stroke Prevention

- Carotid plaque most often causes symptoms due to <u>EMBOLIZATION</u>, rather than thrombosis.
- Extracranial carotid <u>OCCLUSION</u> is the source of ischemic stroke in fewer than 20%.
- Symptomatic patients have a much higher stroke rate than asymptomatic patients.
- Asymptomatic patients outnumber symptomatic patients by 4:1.

#### **RISK FACTOR**

**Blood Pressure** 

**Atrial Fibrillation** 

**Smoking** 

Cholesterol

Diabetes

**Exercise** 

Diet

Stroke in Family




# FACT(s)

#### We do NOT need more trials to establish equipoise for CAS vs. CEA




- 7 systems approved as "safe and effective" by the FDA, all with "pivotal" and post-approval trials, that account for more than 10,000 published cases.
- 3 poorly executed European trials (SPACE, EVA-3s, & ICSS) tell us "trainees" cannot do CAS as well as experienced surgeons can do CEA.
- SAPPHIRE, a small RCT in high surgical risk patients, showed that CAS is the procedure of choice in those pts.
- CREST was a very large, well conducted trial in average risk patients with no difference between CEA and CAS.





# Stroke Prevention










### **BARRIERS** to CAS




- & Low volumes.
- No reimbursement.






### Do I Have to Explain Why Experience Matters?

#### **CREST Lead-In Specialty Outcomes**




Hopkins LN, et al. J. Stroke and Cerebrovascular Dis. 2010;19:153-162



Lin PH, et al. Am J Surg. 2005;190:855-863




#### Unadjusted Patient Outcomes by Annual Operator Volume



Nallamothu, BK et al JAMA. 2011;306(12):1338-1343

#### **CREST**





### The NEW ENGLAND JOURNAL of MEDICINE

**CREST** 

4-Yr Stroke Events

ESTABLISHED IN 1812

JULY 1, 2010

VOL. 363 NO. 1

#### Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis

Table 3. Primary End Point and Its Individual Components among the 1181 Asymptomatic and the 1321 Symptomatic Patients, According to Treatment Group.\*

|  | ar annih annanna annan d | b man amount and ambus | and the same of information | and the second second | and an order |
|--|--------------------------|------------------------|-----------------------------|-----------------------|--------------|
| W. Alice J. Sheffet, Ph.D., Virginia J. Howard, Ph.D., Wesley S. N. L. Nelson Hopkins, M.D., Donald E. Cutlip, M.D., David J. C. Robert D. Ferguson, M.D., Stanley N. Cohen, M.D., Joseph L. & J.P. Mohr, M.D., Brajesh K. Lal, M.D., and James F. Meschia |                          |                        |                             |                       |              |
|  |                          |                        | Absolute Treatment          |                       |              |
| ABSTRACT   |                          |                        | Effect of CAS vs. CEA       | CAS vs. CEA           |              |
| BACKGROUND<br>Carotid-artery stenting and carotid endarterectomy are both options<br>carotid-artery stenosis, an important cause of stroke.  | CAS                      | CEA                    | (95% CI)                    | (95% CI)              | P Value      |
| METHODS  We randomly assigned patients with symptomatic or asymptomatic car to undergo carotid-artery stenting or carotid endarterectomy. The prim   | no. of patient           | ts (% ±SE)             | percentage points           |                       |              |
| Any periprocedural stroke or   |                          |                        |                             |                       |              |
| postprocedural ipsilateral   |                          |                        |                             |                       | 1            |
| stroke   |                          |                        |                             |                       |              |
| Asymptomatic patients  | 24 (4.5±0.9)             | 13 (2.7±0.8            | ) 1.9 (-0.5 to 4.3)         | 1.86 (0.95 to 3.66)   | 0.07         |
| Symptomatic patients   | 48 (7.6±1.1)             | 37 (6.4±1.1            | ) 1.2 (–1.8 to 4.1)         | 1.29 (0.84 to 1.98)   | 0.25         |

stroke (4.1% vs. 2.3%, P=0.01), and for myocardial infarction (1.1% vs. 2.3%, P=0.03). After this period, the incidences of ipsilateral stroke with scenting and with endarterectomy were similarly low (2.0% and 2.4%, respectively, P=0.85).

#### CONCLUSION

Among patients with symptomatic or asymptomatic carotid stenosis, the risk of the composite primary outcome of stroke, myocardial infarction, or death did not differ significantly in the group undergoing carotid-artery stenting and the group undergoing carotid endarterectomy. During the periprocedural period, there was a higher risk of stroke with stenting and a higher risk of myocardial infarction with endarterectomy. (ClinicalTrials.gov number, NCT000004732.)

Clinic, Griffin 304, 4500 San Pablo Rd., Jacksonville, FL 32224, or at brott.thomas@ mayo.edu.

\*Deceased. †The Carotid i

tigators and of listed in the Ap This article (10.10 published on Ma on June 14, 2010, N Engl J Med 2010 No statistical difference for stroke out to 4 years between CAS and CEA.







### **EQUIPOISE FOR CAS & CEA**

WE DON'T NEED MORE TRIALS....WE NEED TO USE THE DATA WE HAVE TO ALLOW PHYSICIANS AND PATIENTS TO MAKE REASONABLE CHOICES, BASED UPON THE EVIDENCE.

- ★ Patients with CAD.
- ★Younger age.
- **Experienced** operator.
- **Experienced** team.






# FACT(s)

"One size does not fit all"


- There <u>IS</u> overall equipoise for CEA and CAS but....
  - Patient selection for CEA/CAS <u>should be individualized</u>.
  - Operator and Institutional volume matter for outcome quality in <u>both CEA and CAS</u>.
  - Symptomatic patients have more to gain than Asx.
  - Younger patients have more to gain, over the long-term, from revascularization, than do the very elderly.



# High Surgical Risk



 Sapphire: Level I evidence supporting equipoise for CAS and CEA.





### CAS Preferred in High Surgical Risk Patients




- Some patients present difficult challenges for CEA, and may be offered CAS as an alternative.
- Some patients who are at increased risk for CEA will strongly prefer CAS.
- Assumes operator and institutional experience and a track record for safety and quality.



### Percent Choosing Treatment Options

- 67-year-old man with a carotid bruit and 70%-80% RICA.
  - nonsmoker
  - hypertension
  - hyperlipidemia
  - LICA 20% stenosis.





## **Asymptomatic Carotid Stenosis**




ACAS<sup>1</sup> and ACST<sup>2</sup> in the 1990's:

- CEA vs. MED
  - 5 yr relative risk reduction for ipsilateral stroke 50%.
  - 1 yr absolute risk reduction of 0.5% to 1.0%.
  - NNT 100-200 to prevent one stroke per year.
  - CFA did not reduce combined stroke and death.
  - CEA did not benefit women.
  - CEA did not benefit men ≥ 75 years.
- CMS 2004-2006
  - Asx CEA = 88%, Asx CAS = 87%.




# **Asymptomatic Carotid Stenosis**


- Risk of progression to occlusion is low.
  - ACST<sup>1</sup>: 1,469 MED Group:
    - 94 progressed to occlusion.
    - 12 with symptoms.
    - 1 with stroke.
  - Yang et al<sup>2</sup>.: 3,681 MED for 20 yrs.
    - 254/316 (80%) Occlusions before 2002.
    - Only 1 stroke with occlusion.





# **Asymptomatic Carotid Stenosis**







### Consensus CAS vs. CEA

#### Asymptomatic

- Selection of asymptomatic patients for revascularization should be based on comorbid conditions and patient life expectancy (Class I, Level of Evidence: C).
- Highly selected patients may benefit from CEA if the perioperative stroke/death rate is <3% (Class IIa, Level of Evidence: A).
- CAS might be considered in highly selected patients if the perioperative stroke/death rate is <3% (Class IIb, Level of Evidence: B).
- The usefulness of CAS is not well established for patients at high risk for CEA (Class IIb, Level of Evidence: C).

#### **Symptomatic**

- Patients with a TIA or stroke ≤ 6 months and ipsilateral severe stenosis (70% to 99%), CEA is recommended if the perioperative stroke/death rate is estimated to be <6% (Class I, Level of Evidence: A).</li>
- CAS is indicated as an alternative to CEA if the anticipated perioperative stroke/death rate is <6% (Class IIa, Level of Evidence: B).
- When revascularization is indicated, it is reasonable to perform it within 2 weeks rather than delay (Class IIa, Level of Evidence: B).
- It is reasonable to consider patient age in choosing between CEA and CAS (Class IIa, Level of Evidence: B).



# FACT(s)


#### Patients hard to operate on safely.

- Class III/IV angina.
- Class III/IV heart failure.
- Intrathoracic or intracerebral lesions.
- Prior neck surgery or RT.



#### Patients hard to place stents safely.


- Type III Aortic Arch.
- Tortuous and calcified lesions.
- Unable to use EPD.
- Difficult vascular access.






## Stroke Prevention Strategy

Revascularization includes aggressive risk factor modification.







# Thank You